# US 2018/0021310 A1 · Mebendazole polymorph for treatement and prevention of tumors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0021310 A1
- Document ID: US20180021310A1
- Status: Published application
- Kind: A1
- Application number: 15/548,959
- Filed: 2016-02-08
- Published: 2018-01-25
- Earliest claimed: 2015-02-06
- Assignees: The Johns Hopkins University
- Applicants: The Johns Hopkins University
- Inventors: Gregory Riggins; Renyuan Bai; Verena Staedtke; Avadhut D. Joshi; Tara Williamson
- Web page: https://patentgrep.com/patent/US20180021310A1

## CPC

- A61K 31/4184: condensed with carbocyclic rings, e.g. benzimidazoles
- A23L 33/10: using additives (addition of substantially indigestible substances A23L33/21)
- A61K 9/0056: {Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals}
- A61K 9/1605: {Excipients; Inactive ingredients}
- A61K 9/50: Microcapsules {having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals (A61K9/2081 takes precedence; particles with a single coating comprising drug A61K9/167)}
- A61K 31/192: having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid {(cannabinoids A61K31/658)}
- A61K 31/473: ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 25/00: Drugs for disorders of the nervous system
- A23V 2002/00: Food compositions, function of food ingredients or processes for food or foodstuffs
- A61P 35/00: Antineoplastic agents
- C07B 2200/13: Crystalline forms, e.g. polymorphs
- G01N 21/35: using infrared light (G01N21/39 takes precedence)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A23V: INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Mebendazole is an antiparasitic drug with over 40 years of safe use. Recently mebendazole was repurposed for glioblastoma therapy. Three polymorphs of mebendazole exist, but the relative polymorph content for existing drugs varies, and the therapeutic anti-cancer relevance of the different polymorphs was unknown. As an oral drug mebendazole polymorph C is a superior form, and it reaches the brain and brain tumors in effective concentrations. Efficacy is further improved by combining mebendazole with a P-glycoprotein inhibitor. Mebendazole may also be used for therapy of other cancers, as well as a chemo-preventative agent.

## Claims

### Claim 1

A pharmaceutical formulation of mebendazole wherein at least 90% of the mebendazole in the formulation is polymorph C, and wherein the formulation is granulated.

### Claim 2 (depends on 1)

The pharmaceutical formulation of claim 1 wherein the granulated formulation is coated.

### Claim 3 (depends on 1)

The pharmaceutical formulation of claim 1 wherein is at least 95% of all mebendazole in the formulation is polymorph C.

### Claim 4 (depends on 1)

The pharmaceutical formulation of claim 1 wherein is at least 98% of all mebendazole in the formulation is polymorph C.

### Claim 5 (depends on 1)

The pharmaceutical formulation of claim 1 wherein is at least 99% of all mebendazole in the formulation is polymorph C.

### Claim 6 (depends on 1)

The pharmaceutical formulation of claim 1 further comprising an inhibitor of P-glycoprotein.

### Claim 7 (depends on 6)

The pharmaceutical formulation of claim 6 wherein the inhibitor of P-glycoprotein is elacridar.

### Claim 8 (depends on 1)

The pharmaceutical formulation of claim 1 further comprising a non-steroidal anti-inflammatory drug (NSAID).

### Claim 9 (depends on 8)

The pharmaceutical formulation of claim 8 wherein the NSAID is sulindac.

### Claim 10

A pharmaceutical formulation of mebendazole comprising polymorph C and an inhibitor of P-glycoprotein.

### Claim 11 (depends on 10)

The pharmaceutical formulation of claim 10 wherein the formulation is granulated.

### Claim 12 (depends on 11)

The pharmaceutical formulation of claim 11 wherein the formulation is coated.

### Claim 13 (depends on 10)

The pharmaceutical formulation of claim 10 wherein the inhibitor of P-glycoprotein is elacridar.

### Claim 14

A pharmaceutical formulation of mebendazole and an NSAID.

### Claim 15 (depends on 14)

The pharmaceutical formulation of claim 14 wherein the formulation is granulated.

### Claim 16 (depends on 15)

The pharmaceutical formulation of claim 15 wherein the formulation is coated.

### Claim 17 (depends on 14)

The pharmaceutical formulation of claim 14 wherein the NSAID is sulindac.

### Claim 18 (depends on 14)

The pharmaceutical formulation of claim 14 wherein the mebendazole comprises polymorph C.

### Claim 19 (depends on 1, 10)

A method of administering the pharmaceutical formulation of one of claims 1, 10, and 14, comprising:
applying the formulation to food prior to ingestion of the food.

### Claim 20 (depends on 19)

The method of claim 19 wherein the food comprises lipids.

### Claim 21 (depends on 19)

The method of claim 19 wherein the pharmaceutical composition comprises a P-glycoprotein inhibitor and the P-glycoprotein inhibitor is is elacridar.

### Claim 22 (depends on 19)

The method of claim 19 wherein the pharmaceutical composition comprises an NSAID and the NSAID is sulindac.

### Claim 23 (depends on 19)

The method of claim 19 wherein the food is ingested by a cancer patient.

### Claim 24 (depends on 19)

The method of claim 19 wherein the food is ingested by a cancer patient with a brain tumor.

### Claim 25 (depends on 19)

The method of claim 19 wherein the food is ingested by a cancer patient with a one of breast, colorectal cancer, and lung tumor.

### Claim 26 (depends on 19)

The method of claim 19 wherein the food is ingested by a cancer patient with a tumor that has a multidrug resistant pump.

### Claim 27 (depends on 19)

The method of claim 19 wherein the food is ingested by an individual at elevated risk of developing colorectal cancer.

### Claim 28 (depends on 27)

The method of claim 27 wherein the individual has familial adenomatous polyposis.

### Claim 29 (depends on 27)

The method of claim 27 wherein the individual has non-hereditary polyposis coli.

### Claim 30

A method to monitor anti-cancer potency of a pharmaceutical formulation of mebendazole, comprising:
assaying the pharmaceutical formulation and determining amount of polymorph C and amount of polymorph A.

### Claim 31 (depends on 30)

The method of claim 30 wherein the step of assaying comprises infrared spectroscopy.

### Claim 32 (depends on 30)

The method of claim 30 wherein the step of assaying is performed at a plurality of times.

### Claim 33 (depends on 1, 10)

A method of treating, or reducing risk of developing, a tumor in a human comprising:
administering to the human or dispensing for oral ingestion by the human the pharmaceutical formulation of one of claims 1, 10, and 14.

### Claim 34 (depends on 33)

The method of claim 33 wherein the tumor is a brain tumor.

### Claim 35 (depends on 34)

The method of claim 34 wherein the brain tumor is a medulloblastoma.

### Claim 36 (depends on 34)

The method of claim 34 wherein the brain tumor is a glioma.

### Claim 37 (depends on 33)

The method of claim 33 wherein the tumor is selected from the group consisting of breast, colorectal, and lung tumors.

### Claim 38 (depends on 33)

The method of claim 33 wherein the tumor has a multidrug resistant pump.

### Claim 39

A kit for treating or reducing risk of tumors, comprising:
mebendazole; and
an inhibitor of P-glycoprotein or a non-steroidal, anti-inflammatory drug.

### Claim 40 (depends on 39)

The kit of claim 39 wherein the mebendazole comprises polymorph C.

### Claim 41 (depends on 39)

The kit of claim 39 wherein the polymorph C comprises at least 90% of all mebendazole in the kit.

### Claim 42 (depends on 39)

The kit of claim 39 which comprises an inhibitor of P-glycoprotein.

### Claim 43 (depends on 39)

The kit of claim 39 which comprises an NSAID.

### Claim 44 (depends on 42)

The kit of claim 42 wherein the inhibitor of P-glycoprotein is elacridar.

### Claim 45 (depends on 43)

The kit of claim 43 wherein the NSAID is sulindac.

### Claim 46

A method of treating or reducing risk of a tumor in a human comprising:
administering or dispensing to the human for oral ingestion:
polymorph C of mebendazole, and
an inhibitor of P-glycoprotein or a non-steroidal, anti-inflammatory drug.

### Claim 47 (depends on 46)

The method of claim 46 wherein an inhibitor of P-glycoprotein is administered or dispensed.

### Claim 48 (depends on 47)

The method of claim 47 wherein the inhibitor of P-glycoprotein is elacridar.

### Claim 49 (depends on 46)

The method of claim 46 wherein the polymorph C comprises at least 90% of all mebendazole administered.

### Claim 50 (depends on 46)

The method of claim 46 wherein a brain tumor is treated.

### Claim 51 (depends on 50)

The method of claim 50 wherein the brain tumor is a medulloblastoma.

### Claim 52 (depends on 50)

The method of claim 50 wherein the brain tumor is a glioma.

### Claim 53 (depends on 46)

The method of claim 46 wherein a tumor is treated, said tumor selected from the group consisting of breast, colorectal, and lung tumors.

### Claim 54 (depends on 53)

The method of claim 53 wherein the tumor has a multidrug resistant pump.

### Claim 55 (depends on 46)

The method of claim 46 wherein a NSAID is administered or dispensed.

### Claim 56 (depends on 55)

The method of claim 55 wherein the NSAID is sulindac.

### Claim 57 (depends on 46)

The method of claim 46 wherein the human has an elevated risk of developing a cancer.

### Claim 58 (depends on 46)

The method of claim 46 wherein the human has an elevated risk of developing a colorectal cancer.

### Claim 59

A method of reducing risk of a tumor in a human comprising:
administering or dispensing to the human for oral ingestion:
mebendazole, and
a non-steroidal, anti-inflammatory drug.
